FIELD: pharmaceutics.
SUBSTANCE: invention relates to a pharmaceutical composition for the treatment of a neuropsychiatric or neurodegenerative disease or disorder containing the effective amount of a remedy with double activity showing CYP2D6 inhibitor activity and reverse agonist activity of 5-HT2A/5-HT2C receptor or antagonist/reverse agonist activity of 5-HT2A receptor, where the specified remedy with double activity is N,N-dimethyl-2-[[(1R,3S,4R)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine; and NMDA receptor antagonist selected from a group consisting of memantine and dextromethorphan (DEX).
EFFECT: pharmaceutical composition with double activity is developed that can provide higher efficiency, such as greater pain relief than would be achieved with the injection of any component separately.
8 cl, 207 ex, 17 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
| SUBSTANCES FOR PANCREATITIS PREVENTION AND TREATMENT | 2006 |
|
RU2423692C2 |
| NEW PHARMACEUTICAL COMPOSITIONS FOR SEXUAL DISORDERS | 2005 |
|
RU2445095C2 |
| BISPHENOL DERIVATIVES AND THEIR USE AS ACTIVITY MODULATORS OF ANDROGEN RECEPTOR | 2017 |
|
RU2767257C2 |
| DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND USING | 2002 |
|
RU2314305C2 |
| BENZOYLAMINOHETEROCYCLYL COUMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | 2007 |
|
RU2440992C2 |
| ALKYL2-{[(2R,3S,5R)-5-(4-AMINO-2-OXO-2H-PYRIMIDINE-1-YL)- -HYDROXY- TETRAHYDRO-FURAN-2-YLMETHOXY]-PHENOXY-PHOSPHORYLAMINO}-PROPTONATES, NUCLEOSIDE INHIBITORS OF RNA-POLYMERASE HCV NS5B, METHODS FOR PRODUCING AND USING THEM | 2013 |
|
RU2534613C2 |
| COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2561109C2 |
| POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | 2017 |
|
RU2750935C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2653500C2 |
